Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2005 1
2006 1
2007 2
2008 1
2009 2
2010 1
2021 1
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study.
Passamonti F, Palandri F, Saydam G, Callum J, Devos T, Guglielmelli P, Vannucchi AM, Zor E, Zuurman M, Gilotti G, Zhang Y, Griesshammer M. Passamonti F, et al. Among authors: zuurman m. Lancet Haematol. 2022 Jul;9(7):e480-e492. doi: 10.1016/S2352-3026(22)00102-8. Epub 2022 May 18. Lancet Haematol. 2022. PMID: 35597252 Clinical Trial.
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
Theocharides A, Gisslinger H, De Stefano V, Accurso V, Iurlo A, Devos T, Egyed M, Lippert E, Delgado RG, Cantoni N, Dahm AEA, Sotiropoulos D, Houtsma E, Smyth A, Iqbal A, Di Matteo P, Zuurman M, Te Boekhorst PAW. Theocharides A, et al. Among authors: zuurman m. Eur J Haematol. 2024 Mar;112(3):379-391. doi: 10.1111/ejh.14124. Epub 2023 Oct 30. Eur J Haematol. 2024. PMID: 37899734
Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera-Advanced Integrated Models (PV-AIM) Project.
Verstovsek S, Krečak I, Heidel FH, De Stefano V, Bryan K, Zuurman MW, Zaiac M, Morelli M, Smyth A, Redondo S, Bigan E, Ruhl M, Meier C, Beffy M, Kiladjian JJ. Verstovsek S, et al. Among authors: zuurman mw. Biomedicines. 2023 Jul 7;11(7):1925. doi: 10.3390/biomedicines11071925. Biomedicines. 2023. PMID: 37509564 Free PMC article.
Chemokines in the brain: neuroimmunology and beyond.
Biber K, Zuurman MW, Dijkstra IM, Boddeke HW. Biber K, et al. Among authors: zuurman mw. Curr Opin Pharmacol. 2002 Feb;2(1):63-8. doi: 10.1016/s1471-4892(01)00122-9. Curr Opin Pharmacol. 2002. PMID: 11786310 Review.
JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy.
Vannucchi AM, Mortara A, D'Alessio A, Morelli M, Tedeschi A, Festuccia MB, Monforte AD, Capochiani E, Selleri C, Simonetti F, Saracino A, Rapezzi D, Badagliacca MR, Falasca K, Molteni A, Palazzolo R, Schettino G, Bocchia M, Turrini M, Ascierto PA, Zuurman M, Paley C, Coco P, Saglio G. Vannucchi AM, et al. Among authors: zuurman m. J Clin Med. 2021 Aug 23;10(16):3752. doi: 10.3390/jcm10163752. J Clin Med. 2021. PMID: 34442045 Free PMC article.
CCR5 deletion protects against inflammation-associated mortality in dialysis patients.
Muntinghe FL, Verduijn M, Zuurman MW, Grootendorst DC, Carrero JJ, Qureshi AR, Luttropp K, Nordfors L, Lindholm B, Brandenburg V, Schalling M, Stenvinkel P, Boeschoten EW, Krediet RT, Navis G, Dekker FW. Muntinghe FL, et al. Among authors: zuurman mw. J Am Soc Nephrol. 2009 Jul;20(7):1641-9. doi: 10.1681/ASN.2008040432. Epub 2009 Apr 23. J Am Soc Nephrol. 2009. PMID: 19389855 Free PMC article.
16 results